Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$14,883.75
Dec 20, 2022
For-profit organization
Develop digital adoption plan
$75,000.00
Dec 5, 2022
For-profit organization
ARP - Obtaining the CE mark.
998987
Obtaining the CE mark, allowing to be recognized and prescribed on the European market as a digital therapy.
$185,900.00
Dec 5, 2022
For-profit organization
Development of a Quantitative Assay to Measure Drug Metabolites for Cancer Treatment.
999524
Development of a safe, effective and affordable drug biomarker test to assess and monitor response to cancer therapy.
$10,000.00
Dec 1, 2022
Individual or sole proprietorship
Institute Community Support Grant
168286
The ICS Program is designed to foster community development by providing grants and awards to individuals and organizations for the purposes of:
Enabling research and knowledge translation activities where the circumstances fall outside of CIHR's current suite of funding programs.
Supporting individuals and organizations whose goals are consistent with CIHR and its Institutes' vision, mandate and strategic directions.
The ICS Program is not intended to support the direct cost of research (e.g., pilot projects, feasibility studies or operating grants), principal and co-investigator salaries or research equipment.
$15,000.00
Nov 15, 2022
For-profit organization
Develop digital adoption plan
$385,000.00
Nov 1, 2022
Academia
Discovery of Single-Cell Omics Biomarkers in Alveolar Macrophages for Immunotherapy of Chronic Obstructive Pulmonary Disease
994662
The primary objective of this study is to develop digital technologies to discover AM biomarkers for novel COPD therapy by integrating both bulk and single cell omics data.
$75,000.00
Nov 1, 2022
For-profit organization
ToeFX Marketing Systems Development
997863
The ClearToe Therapy Light by ToeFX is the first photodisinfection technology authorized for sale by Health Canada for the clearance of fungal nails.
$14,849.73
Oct 25, 2022
For-profit organization
Develop digital adoption plan
$365,516.00
Oct 17, 2022
Aboriginal recipient
Culture to Wellness: Reimagining Holistic Healing Approaches for Indigenous Women, Girls and 2SLGBTQQIA+ People
SO220008
This will be achieved by orienting Aboriginal Legal Services staff to new ways of combining traditional Indigenous healing methods with music therapy designed for trauma survivors; conducting workshops with staff to deepen their knowledge and ability to share and adapt new healing models; conducting outreach to local Indigenous stakeholders; and holding community workshops to test new healing strategies.
$285,000.00
Sep 26, 2022
For-profit organization
Neuromuscular junction-on-a-chip for rapid diagnosis of neuromuscular diseases and applications in precision medicine
997002
Neuromuscular diseases (NMDs) affect approximately 13 million worldwide, there is no cure and no effective therapy. There is a major need for robust, scalable, and reproducible in vitro models of human neuromuscular junctions (NMJ) to test therapeutic candidates.